Which joint pain relief option fits your soreness?

What does the first visit check?

The clinician asks where and when your joint hurts. Expect questions about swelling, stiffness, falls, and old injuries. The exam checks how you move and where it hurts most. You won't always need blood work or an X-ray.

Take along medicines, supplements, and old joint reports. Name the daily task that has become hard. Don't only say that earlier care failed. Explain what you did and whether anything changed.

What non-surgical choices can you discuss?

Exercise, shorter work periods, braces, and walking aids may help. Pain medicine spread over the skin doesn't reach every joint well. Pills for soreness can harm kidneys or strain the heart. Ask your doctor to check them against your other medicines.

Regenerative treatments at QC Kinetix are clinic shots made from your blood or from marrow taken from a bone. For PRP, blood is drawn before the portion rich in platelets is prepared. A medical provider (the clinician who checks your joint and performs this care) explains each choice. The visit can also cover knee or hip surgery alternatives.

When does surgery enter the talk?

A doctor may discuss surgery after finding the painful joint. The X-ray doesn't help unless it shows damage there too. Ask which daily task the operation is expected to restore. Don't forget to ask what recovery requires at home.

You don't have to rush into an operation. Yet you may be unable to walk, work, or sleep well. Your health and help at home affect the timing. Compare surgery with non-surgical care before you decide.

Sources

1. A Cochrane overview of 21 systematic reviews (381 studies, 37,143 participants) covering rheumatoid arthritis, osteoarthritis, fibromyalgia, low back pain, neck disorder and other chronic pain conditions concluded that physical activity and exercise are interventions with few adverse events that may improve pain severity and physical function - but that the quality of the evidence is low, effects on pain were inconsistent across reviews, and physical function improved significantly in 14 reviews with only small-to-moderate effect sizes. The commonest reported adverse event was increased muscle soreness that settled within weeks.

   Geneen LJ, Moore RA, Clarke C, Martin D, Colvin LA, Smith BH — Physical activity and exercise for chronic pain in adults: an overview of Cochrane Reviews.. Cochrane Database of Systematic Reviews, 2017. DOI: 10.1002/14651858.CD011279.pub3.

2. OARSI's 2019 guideline is the only major osteoarthritis guideline that grades treatments separately for people with disease in MULTIPLE joints. Its Core Treatments for polyarticular OA are arthritis education and structured land-based exercise. Critically, intra-articular corticosteroid and intra-articular hyaluronic acid were Level 1B/2 options for knee OA only and were NOT recommended for hip or polyarticular OA; oral NSAIDs were not recommended at all for people with cardiovascular comorbidity or frailty; and paracetamol/acetaminophen was conditionally not recommended.

   Bannuru RR, Osani MC, Vaysbrot EE, et al. — OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis.. Osteoarthritis and Cartilage, 2019. DOI: 10.1016/j.joca.2019.06.011.

3. FDA states verbatim that of the products marketed as regenerative medicine - stem cell products, stromal vascular fraction from adipose tissue, umbilical cord blood, Wharton's jelly, amniotic fluid and exosome products - 'None of these products have been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming (hematopoietic progenitor) cells from umbilical cord blood, approved only for disorders of blood production, and there are currently no FDA-approved exosome products.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA (Center for Biologics Evaluation and Research), 2024.

4. A systematic review of 25 observational studies (15 rated high quality) found moderate evidence that overweight is associated with developing osteoarthritis of the HAND - a joint that carries none of the body's weight - with an approximate risk ratio of 1.9. That association is the standard argument that body weight acts on joints systemically, not only mechanically.

   Yusuf E, Nelissen RG, Ioan-Facsinay A, et al. — Association between weight or body mass index and hand osteoarthritis: a systematic review.. Annals of the Rheumatic Diseases, 2010. DOI: 10.1136/ard.2008.106930.

5. In the 454-person IDEA randomized trial, 18 months of intensive diet plus exercise produced 10.6 kg (11.4%) mean weight loss and less pain and better function than either diet alone or exercise alone in overweight and obese adults aged 55 and older with painful radiographic knee OA. The exercise-only group lost 1.8 kg (2.0%).

   Messier SP, et al. — Effects of intensive diet and exercise on knee joint loads, inflammation, and clinical outcomes among overweight and obese adults with knee osteoarthritis: the IDEA randomized clinical trial.. JAMA, 2013. DOI: 10.1001/jama.2013.277669.

6. In a 68-week double-blind placebo-controlled trial of 407 participants with obesity and moderate knee osteoarthritis, once-weekly semaglutide 2.4 mg produced -13.7% body weight change versus -3.2% with placebo, and a WOMAC pain change of -41.7 points versus -27.5 with placebo (P<0.001 for both), with a greater SF-36 physical-function gain.

   Bliddal H, et al. — Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.. N Engl J Med, 2024. DOI: 10.1056/NEJMoa2403664.